NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Questex’s Fierce Biotech announces the 2024 Fierce Biotech Summit, the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials, will take place September 30-October 1 in Boston. Register here.
Created by the editors behind Fierce Biotech, the two-day Summit brings together leaders and executives to discuss advancements and the potential of new innovations. With the theme “Rebuilding: What’s Next for Biotech,” the Summit focuses on the future of biotech, covering topics such as the biotech IPO outlook, developments in cell therapy and the transition from corporate communications to corporate affairs. Experts in the industry will dive deep into how the industry has navigated regulatory challenges and market changes through strategic deals and innovative approaches.
“Our conference offers a unique opportunity for biotech executives to learn how to improve their partnership and pipeline strategies. We are excited to connect with industry leaders to gain insights into the future landscape of biotech,” said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare.
The Summit’s agenda features four tracks:
- NEW: Preclinical & CMC
- NEW: PR & Communications
- Strategy & Dealmaking
- Early-Stage Development
Key panel sessions include:
- Charting the Biotech IPO Frontier: Market Trends, Financial Outlook, and Future Projections
- Evolution from Corporate Communications to Corporate Affairs
- The Obesity Drug Boom
- CAR-Ts: From Oncology Superstars to Autoimmune Upstarts
- Political Pathways: Navigating the 2024 Election Cycle in Biotech
- Strategic Insights: Navigating Biotech M&A and Dealmaking Landscape in 2024 and Beyond
Presentations will be delivered by companies who are pioneering innovative ideas and new technologies to drive the industry forward, including:
- Rose Loughlin, PhD, Senior Vice President, Research and Early Development, Moderna
- Natacha Gassenbach, Chief Communications Officer, SVP Corporate Affairs, Biogen
- David R. Shook, M.D., Chief Medical Officer, Nkarta, Inc.
- Karin Conde-Knape, Senior Vice President for Global Drug Discovery, Novo Nordisk
- R. Nolan Townsend, CEO, LEXEO
- Kym White, Chief Corporate Affairs Officer, Generate:Biomedicines
- Adam Friedman M.D., CEO, Scorpion Therapeutics
View the agenda here.
The Fierce Biotech Summit will also celebrate top biotech innovators at the Fierce Biotech Fierce 15 awards ceremony.
For more information on the Fierce Biotech Summit, visit fiercebiotechsummit.com. To register click here.
Premier Fierce Biotech Summit partners are: Asymchem, Hogan Lovells, Guidehouse, Marina Maher Communications and Syneos Health.
For sponsorship opportunities, contact Brandon Pepper, Sales Director at bpepper@questex.com.
Stay connected on LinkedIn and X.
About Fierce Biotech
Fierce Biotech is the biotech industry's daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free here.
About Questex
Questex helps people live better and longer. Questex brings people together in the markets that help people live better: travel, hospitality and wellness; the industries that help people live longer: life science and healthcare; and the technologies that enable and fuel these new experiences. We live in the experience economy – connecting our ecosystem through live events, surrounded by data insights and digital communities. We deliver experience and real results. It happens here.
Media Contact
Linda Lam
Director of Marketing
Fierce Biotech Summit
llam@questex.com
